No Data
No Data
Earnings Preview: MIRM to Report Financial Results Post-market on May 07
Mirum Pharmaceuticals (MIRM) Receives a Buy From Evercore ISI
FDA Approves Mirum Pharma's Livmarli Tablet Formulation For Treatment Of Cholestatic Pruritus In Patients With Alagille Syndrome And Progressive Familial Intrahepatic Cholestasis
Express News | Mirum Pharmaceuticals Inc - Livmarli Tablets to Be Available in June
Express News | Mirum’s Livmarli Now FDA Approved in Tablet Formulation
Express News | Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)